2-甲基-2-丙基(2-甲基-2-丙烯-1-基)氨基甲酸酯 | 91230-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-甲基-2-丙基(2-甲基-2-丙烯-1-基)氨基甲酸酯
• 中文别名: 丙酸2-羟基-乙烯基酯(9CI)
• 英文名称: tert-butyl (2-methylallyl)carbamate
• 英文别名: tert-butyl N-(2-methylprop-2-enyl)carbamate
• CAS: 91230-06-7
• 化学式: C₉H₁₇NO₂
• mdl: MFCD24465623
• 分子量: 171.239
• InChiKey: KNDCLOGKZOTPEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基(2-甲基-2-丙烯-1-基)氨基甲酸酯 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 0.5h， 生成 1-<<(tert-butoxycarbonyl)amino>methyl>-1-methyloxirane
  参考文献：
  名称：

  Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

  摘要：

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.

  DOI：

  10.1021/jm00017a016
• 作为产物：
  描述：

  N-(p-toluenesulfonyl)-N-(tert-butoxycarbonyl)-methallylamine 在 甲醇 、 magnesium 作用下， 反应 0.5h， 生成 2-甲基-2-丙基(2-甲基-2-丙烯-1-基)氨基甲酸酯
  参考文献：
  名称：

  N-甲硅烷基系自由基环化：γ-氨基醇的新合成。

  摘要：

  [反应：见正文]在N-甲硅烷基连接的自由基环化反应中已使用了各种带有保护基（PG）的烯丙基和炔丙基胺。生成的硅吡咯烷加合物可以被平滑氧化，从而获得γ-氨基醇。甲硅烷基化，自由基环化和氧化反应可以通过一锅法进行合并。

  DOI：

  10.1021/ol034288j

文献信息

• [EN] CYP11A1 INHIBITORS<br/>[FR] INHIBITEURS DE CYP11A1
  申请人：ORION CORP

  公开号：WO2021229152A1

  公开（公告）日：2021-11-18

  The present invention relates to a compound of formula (I) or (II) wherein R1, R2, R3, R4, R5, R23, R24, R25, R26, R27, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) or (II) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

  本发明涉及一种具有式（I）或（II）的化合物，其中R1、R2、R3、R4、R5、R23、R24、R25、R26、R27、L、A和B如权利要求书中所定义，或其药学上可接受的盐。式（I）或（II）的化合物具有作为细胞色素P450单加氧酶11A1（CYP11A1）抑制剂的效用。这些化合物在治疗类固醇受体，特别是雄激素受体依赖性疾病和症状，如前列腺癌中作为药物是有用的。
• DNA-PK INHIBITORS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130281431A1

  公开（公告）日：2013-10-24

  The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为DNA-PK抑制剂的化合物。该发明还提供了包含所述化合物的药物可接受的组合物，以及使用所述组合物治疗各种疾病、状况或失调的方法。
• Direct Catalytic Synthesis of Unprotected 2-Amino-1-Phenylethanols from Alkenes by Using Iron(II) Phthalocyanine
  作者：Luca Legnani、Bill Morandi

  DOI：10.1002/anie.201507630

  日期：2016.2.5

  medicinal chemistry and natural products. Herein, we report that an exceptionally simple and inexpensive FeII complex efficiently catalyzes the direct transformation of simple alkenes into unprotected amino alcohols in good yield and perfect regioselectivity. This new catalytic method was applied in the expedient synthesis of bioactive molecules and could be extended to aminoetherification.

  芳基取代的氨基醇是药物化学和天然产物中的特有支架。本文中，我们报道了异常简单和廉价的Fe II络合物有效地催化了简单烯烃的直接转化为未保护的氨基醇，并具有良好的收率和良好的区域选择性。这种新的催化方法被应用于生物活性分子的方便合成，并可以扩展到氨基醚化。
• A Flexible, Convergent Approach to Polycyclic Indole Structures: Formal Synthesis of (±)-Mersicarpine
  作者：Aurélien Biechy、Samir Z. Zard

  DOI：10.1021/ol900996k

  日期：2009.7.2

  The formal synthesis of (±)-mersicarpine was achieved using an intermolecular radical addition−radical cyclization cascade. This key reaction represents a flexible, convergent route to numerous polycyclic indole derivatives.

  （±）-美沙芬的正式合成是通过分子间自由基加成-自由基环化级联反应实现的。该关键反应代表了向多种多环吲哚衍生物的灵活收敛路径。
• Synthesis of dibenzo[c,e][1,2]diazocines—a new group of eight-membered cyclic azo compounds
  作者：Tomomi Nokubi、Stephanie Kindt、Timothy Clark、Akio Kamimura、Markus R. Heinrich

  DOI：10.1016/j.tetlet.2014.11.064

  日期：2015.1

  Despite of a remarkable ring strain hitherto unknown dibenzo[c,e][1,2]diazocines 3 could be prepared from readily available azo compounds 4 under mild Ullmann-type reaction conditions. The obtained stereoisomers of the new heterocycles 3 were structurally assigned by 2D NMR experiments and DFT calculations.

  尽管有显着的环应变，但迄今仍可在温和的Ullmann型反应条件下由易于获得的偶氮化合物4制备出未知的二苯并[ c，e ] [1,2]重氮电影3。通过2D NMR实验和DFT计算在结构上分配了获得的新杂环3的立体异构体。